Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (52)	1/17/2000 3:18:00 PM
From: JMarcus	Read Replies (2) \| Respond to of 255

At the 11/20/1999 Informed Investors Forum Kellie Seringer, Biotech Analyst of Evolution Capital, was effusive in her praise of ARDM. The rebroadcast of her comments may still be available at broadcast.com (I forget how long they keep the archives). In contrasting ARDM's technology to INHL's she made the following points: (1) ARDM's device keeps an electronic record of each administration; physicians will love this feature, because they can download the data and monitor exactly how the patient is taking his/her medication; (2) ARDM's device has an electronic lock-out feature (this was a big factor in Kellie predicting that ARDM's product for breakthrough pain, using a regulated substance, will eclipse Anesta's product); and (3) ARDM's devise allows for precise calibration of the dosing; INHL requires the user to purchase and use the entire amount of one or more prepackaged doses in cartridges--the entire contents of the cartridge is used upon an application: you can't set the device for a partial dose. There is a workaround, but it is not very convenient. I.e., if you need three units and the cartridges come in one unit and five unit sizes, you can separately administer to yourself three one-unit cartridges. With ARDM's device, you can calibrate the dosing precisely. There may have been additional features that Kellie liked about ARDM, but these are the ones that I remember. Marc

To: software salesperson who wrote (52)	1/23/2000 12:03:00 PM
From: rkrw	Read Replies (1) \| Respond to of 255

<<rkrw, interested in your view on ardm vs. inhl's competing dry powder product. (i)which do you think has a better chance of clinical success over the next 1-3 years?>> INHL is clearly ahead in its insulin development and barring the unforeseen it will be the first product amongst the two companies to hit the market. In three years time Aradigm should be very close to hitting the market with multiple products. <<(ii) which approach has the greater longer term market potential?>> I think you're looking at it too much as an either, or scenario. Its going to be more about what products they choose to develop and with whom as opposed to which approach will work better, imo. Seems to me that both approaches are feasible.